No connection

Search Results

MRK vs PIII

MRK
Merck & Co., Inc.
NEUTRAL
Price
$121.25
Market Cap
$299.79B
Sector
Healthcare
AI Confidence
90%
PIII
P3 Health Partners Inc.
BEARISH
Price
$2.50
Market Cap
$507.9M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
MRK
16.66
PIII
--
Forward P/E
MRK
12.42
PIII
-11.9
P/B Ratio
MRK
5.7
PIII
-0.05
P/S Ratio
MRK
4.61
PIII
0.35
EV/EBITDA
MRK
11.46
PIII
-1.53

Profitability

Gross Margin
MRK
77.21%
PIII
-4.12%
Operating Margin
MRK
32.77%
PIII
-39.98%
Profit Margin
MRK
28.08%
PIII
-10.14%
ROE
MRK
36.88%
PIII
-6952.57%
ROA
MRK
12.04%
PIII
-23.46%

Growth

Revenue Growth
MRK
5.0%
PIII
3.8%
Earnings Growth
MRK
-19.3%
PIII
--

Financial Health

Debt/Equity
MRK
0.96
PIII
--
Current Ratio
MRK
1.54
PIII
0.24
Quick Ratio
MRK
0.96
PIII
0.22

Dividends

Dividend Yield
MRK
2.83%
PIII
--
Payout Ratio
MRK
45.05%
PIII
0.0%

AI Verdict

MRK NEUTRAL

MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.

Strengths
Strong profitability (28.1% margin)
Strong ROE of 36.9%
Risks
Premium vs Graham Number ($59.01)
Weak financial trend (Piotroski F-Score: 3/9)
PIII BEARISH

P3 Health Partners exhibits severe financial distress, characterized by a Piotroski F-Score of 4/9 which barely maintains a 'stable' rating despite catastrophic balance sheet metrics. The company is operating with negative equity (Price/Book: -0.05) and a critical liquidity crisis, evidenced by a Current Ratio of 0.24. Massive operating losses and a staggering ROE of -6952.57% indicate a failing business model. With a 5-year price decline of 99.5% and consistent earnings misses, the company faces significant insolvency risk.

Strengths
Low Price-to-Sales ratio (0.35) suggests low valuation relative to revenue
Marginal positive revenue growth (3.80% YoY)
Analyst target price ($3.50) sits above current market price
Risks
Critical liquidity shortage with a Current Ratio of 0.24
Negative shareholder equity (Price/Book -0.05)
Extreme operational inefficiency with -39.98% operating margins

Compare Another Pair

MRK vs PIII: Head-to-Head Comparison

This page compares Merck & Co., Inc. (MRK) and P3 Health Partners Inc. (PIII) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile